Eli Lilly said a Phase 2 clinical trial for its treatment to inhibit lipoprotein(a) formation met its primary endpoint. Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed ...
On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...
The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...
The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...
Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.
State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...
Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.
Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...
Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...
Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...